Back to top
more

Corcept Therapeutics (CORT)

(Delayed Data from NSDQ)

$47.62 USD

47.62
1,462,070

-1.35 (-2.76%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $47.70 +0.08 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMA

Alnylam's (ALNY) RNAi candidate, patisiran, has been granted accelerated assessment by the European Medicines Agency. The company expects to file new drug application by end of 2017.

    Glaxo's Subcutaneous Formulation of Benlysta Approved in EU

    GlaxoSmithKline's (GSK) Benlysta receives approval for a new subcutaneous formulation in Europe as an add-on therapy for patients with SLE.

      The Zacks Analyst Blog Highlights: Micron Technology, Meritor, RH, Ultra Clean Holdings and Corcept Therapeutics

      The Zacks Analyst Blog Highlights: Micron Technology, Meritor, RH, Ultra Clean Holdings and Corcept Therapeutics

        Nilanjan Choudhury headshot

        5 Stocks That Doubled in 2017 and Can Keep Soaring Higher

        The strong stock rally does not necessarily indicate that all scrips would be wise picks.

          Corcept (CORT) Q3 Earnings Miss Estimates, Guidance Raised

          Corcept Therapeutics' (CORT) earnings miss but sales beat expectations in the third quarter of 2017. The company remains focused on advancing its cortisol modulation platform.

            Pfizer's sNDA for Bosulif Accepted in the U.S. and Europe

            Pfizer (PFE) along with Avillion announced that the regulatory authorities in the U.S. and Europe have accepted the application for label expansion of Bosulif to include newly diagnosed patients.

              Top Ranked Momentum Stocks to Buy for August 29th

              Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 29th:

                Mylan and Otsuka Ink Agreement to Commercialize Deltyba

                Mylan (MYL) and Otsuka Pharmaceutical have entered into a license agreement to commercialize Deltyba in developing countries.

                  Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars

                  Adamas Pharmaceuticals' (ADMS) Gocovri was approved by the FDA for treating dyskinesia in patients with Parkinson's disease. This led to an upside in shares.

                    BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End

                    BioDelivery Sciences (BDSI) President and CEO, Mark Sirgo, is set to retire this year.

                      Lannett (LCI) Q4 Earnings In Line, Stock Up on Solid View

                      Lannett (LCI) reported in-line Q4 earnings and sales. The FDA approved multiple pending ANDAs during the quarter. Also, the company provided strong outlook for 2018.

                        Why Corcept Therapeutics (CORT) Could Be Positioned for a Surge

                        Corcept Therapeutics (CORT) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

                          Can The Uptrend Continue for Corcept Therapeutics (CORT)?

                          Investors certainly have to be happy with Corcept Therapeutics Incorporated (CORT) and its short term performance

                            Top Ranked Momentum Stocks to Buy for August 7th

                            Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 7th:

                              Corcept (CORT) Looks Good: Stock Moves Up 8.8% in Session

                              Corcept Therapeutics Incorporated (CORT) moved big last session, as its shares rose over 8% on the day.

                                Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised

                                Corcept Therapeutics Incorporated's (CORT) top line was driven by the strong sales of its only market drug Korlym. Thus the company raised its 2017 revenue guidance.

                                  Vertex (VRTX) Triple Combination CF Studies Data Positive

                                  Vertex announced positive data from three studies evaluating three different triple combination regimens. These demonstrated pronounced improvements in lung function in CF patients.

                                    Corcept Therapeutics Focuses on Korlym's Label Expansion

                                    We issued an updated research report on Corcept Therapeutics Incorporated (CORT) on Jul 12.

                                      Why is Corcept's Stock Up More Than 60% So Far This Year?

                                      Shares of Corcept Therapeutics Incorporated (CORT) has soared 62.5% this year so far, massively outperforming the 5.6% increase registered by the Zacks classified Medical Drugs industry during this period.

                                        Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View

                                        Bristol-Myers Squibb Company's (BMY) first-quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14% from the year-ago period.

                                          Nivalis' (NVLS) Shares Down After Merger Deal with Alpine

                                          The announcement of Nivalis Therapeutics, Inc.'s (NVLS) merger agreement with a privately-held biotechnology company, Alpine Immune Sciences, Inc. failed to excite investors.

                                            AMAG Files for FDA Approval of Subcutaneous Form of Makena

                                            AMAG Pharmaceuticals, Inc. (AMAG) announced the submission of a supplemental New Drug Application (sNDA) to the FDA for the subcutaneous auto-injector form of its marketed drug Makena in the U.S.

                                              Corcept (CORT) Up 18% Since Earnings Report: Can It Continue?

                                              Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                Corcept (CORT) Strives to Commercialize Key Drug Korlym

                                                We issued an updated report on Corcept Therapeutics Incorporated (CORT) on Mar 28.

                                                  Corcept Korlym Positive in Phase I/II Breast Cancer Study

                                                  Corcept Therapeutics (CORT) announced encouraging efficacy data from a phase I/II study on Korlym in patients with metastatic triple-negative breast cancer.